Your panel came back flagged. Your doctor wrote a prescription. No one in that appointment told you the cutoff that triggered the flag was lowered by a committee, a percentage of whom had documented financial ties to the manufacturer of the drug you just left with. That distinction matters more than anything else in your chart. Because if the threshold moved and your biology did not, then the intervention that follows is treating a definition, not a mechanism. And the actual driver keeps running.
The Chronic Disease Spike Was Built in Conference Rooms, Not Clinics
Look at the trend lines for diabetes, high cholesterol, and hypertension across the last three decades. Each one follows a similar pattern: a gradual upward slope, then a vertical cliff. Not a curve. A cliff. The kind of change that does not happen because millions of people’s bodies suddenly deteriorated in the same calendar year.
What changed was the definition of the disease. In November 2017, a panel of cardiologists voted to drop the hypertension threshold from 140 over 90 to 130 over 80. Same people. Same readings. Brand new category. Thirty-one million Americans became hypertensive overnight without their blood pressure moving a single point. The UK, Europe, Canada, Japan, and Australia looked at the identical scientific evidence and declined to follow.
The cholesterol story follows the same structure. In 1988, normal LDL was set at 190. By 2001, a committee dropped it to 130. Statin prescriptions doubled within three years. In 2013 they lowered it again, and 12.9 million people were newly diagnosed with high cholesterol in a single stroke. Today roughly 86 million Americans carry that diagnosis, and the majority are on medication.
Then came the construction that should concern you most if you are in the performance window of your career:
- A new category called prediabetes was created by lowering the blood sugar threshold
- Seventy-two million people became prediabetic without their glucose changing
- Combined with existing diabetes diagnoses, roughly 115 million adults now sit in that bucket
- The committees that set these thresholds included members with documented financial ties to the pharmaceutical industry
- The threshold changes did not extend mortality or improve measured health outcomes
This is not a conspiracy argument. It is a documented pattern, examined in peer-reviewed literature and by standing campaigns in publications like the British Medical Journal. The point is not that these conditions are fictitious. The point is that the spikes on those graphs are largely manufactured, and your fear of the number on your lab report may be calibrated to a threshold designed for a different purpose than your health.
The Mechanism That Actually Drives All Three Conditions
Here is what the threshold debate tends to bury. Whether the cutoff is accurate or not, the underlying driver for all three of these conditions is the same. It is not LDL. It is not blood pressure in isolation. It is chronic insulin elevation, and it rarely appears on a standard annual panel.
Insulin is the hormone your pancreas releases when glucose enters your bloodstream. In a healthy metabolic environment, it rises briefly after a meal and returns to baseline. In a high-output, high-carbohydrate, high-stress environment, it stops returning to baseline. It stays elevated. And chronically elevated insulin is not a benign background condition.
Here is what chronic insulin elevation does to the systems your performance depends on:
- Stiffens arterial walls, which drives blood pressure up
- Increases cholesterol production, particularly LDL and triglycerides
- Drives insulin resistance, where cells stop responding to insulin’s signal
- Progresses toward prediabetes and eventually type 2 diabetes
- Sustains systemic inflammation, which degrades recovery, cognition, and sleep quality
Notice that these are not three separate diseases. They are three downstream expressions of one broken signal. Your blood pressure reading, your LDL number, your fasting glucose, they are outputs. Insulin is the input. Treating the outputs with separate medications while leaving the input untouched is not root cause medicine. It is symptom management with a very long prescription pad.
The primary fuel source for chronic insulin elevation is a sustained high intake of refined carbohydrates and refined starches. Not dietary fat. Not red meat. The diet that became standard in the same decades these disease rates climbed. That timing is not coincidental.
What the Evidence Shows About Addressing the Actual Driver
If the mechanism is insulin elevation and the primary fuel is refined carbohydrate intake, then the intervention logic is not complicated. You reduce the fuel load, you support the downstream signals, and you measure what is actually happening metabolically rather than waiting for a threshold to flag you.
The research on this is stronger than most standard-of-care conversations acknowledge. A landmark study on dietary intervention for type 2 diabetes showed full reversal in 46 out of 100 participants after 12 months. Not management. Reversal. That finding should be the first thing communicated in a clinical conversation before a prescription is written. Informed consent requires that alternatives be presented. They frequently are not.
For LDL, the following have demonstrated measurable impact in the research:
- Low-carbohydrate dietary patterns
- Consistent aerobic exercise
- Red yeast rice
- Niacin, which also raises HDL
- Plant sterols
For blood pressure, the evidence supports stacking multiple inputs rather than relying on a single lever:
- Garlic supplementation
- Hibiscus tea consumed consistently
- The DASH dietary pattern combined with sodium reduction
- Regular exercise
- Increasing potassium relative to sodium intake
- Magnesium supplementation
The standard objection is that randomized controlled trials have not tested all of these stacked together, so the evidence is considered incomplete. That objection is technically accurate and practically useless. A randomized controlled trial is designed to isolate one variable. Human physiology does not run on one variable. The absence of a trial testing the full stack is a limitation of the research methodology, not evidence that the stack does not work. Stacking lifestyle interventions is exactly how the metabolic environment gets corrected at the level of the signal, not the symptom.
What you are not being told in a standard fifteen-minute appointment is this:
- The threshold that flagged your number may have been set by a committee with financial conflicts
- The same number was considered normal under the previous standard
- The underlying driver may be insulin-related and entirely addressable without pharmaceutical intervention
- Dietary and lifestyle changes have demonstrated reversal, not just management, in peer-reviewed research
- Starting one medication for a side-effect threshold frequently initiates a chain of additional prescriptions
None of this means every diagnosis is manufactured or every prescription is wrong. Some people need medication. The issue is the sequence. The root cause assessment should come before the prescription pad. Right now, in most clinical settings, it does not.
Within the next 24 hours, pull your most recent lab work and locate your fasting insulin. If it was not tested, that absence is itself information worth acting on. Fasting insulin is one of the earliest indicators of metabolic dysregulation, and it is not included in most standard panels. Note what was measured and what was not, and bring that question to your next clinical conversation. At Metabolic Reboot, the starting point is always the signals that standard care skips, because a number flagged against a compromised threshold tells you almost nothing about what is actually driving the pattern.